These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18321611)

  • 21. The discovery of equipotent PPARalpha/gamma dual activators.
    Martres P; Faucher N; Laroze A; Pineau O; Fouchet MH; Potvain F; Grillot D; Beneton V
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6251-4. PubMed ID: 18947994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
    Kasuga J; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of potent PPARalpha agonists.
    Sauerberg P; Mogensen JP; Jeppesen L; Bury PS; Fleckner J; Olsen GS; Jeppesen CB; Wulff EM; Pihera P; Havranek M; Polivka Z; Pettersson I
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3198-202. PubMed ID: 17379517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
    Shi GQ; Dropinski JF; McKeever BM; Xu S; Becker JW; Berger JP; MacNaul KL; Elbrecht A; Zhou G; Doebber TW; Wang P; Chao YS; Forrest M; Heck JV; Moller DE; Jones AB
    J Med Chem; 2005 Jun; 48(13):4457-68. PubMed ID: 15974597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Jan; 44(1):42-53. PubMed ID: 18448203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
    Li Z; Liao C; Ko BC; Shan S; Tong EH; Yin Z; Pan D; Wong VK; Shi L; Ning ZQ; Hu W; Zhou J; Chung SS; Lu XP
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3507-11. PubMed ID: 15177462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.
    Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
    J Med Chem; 2007 Aug; 50(16):3954-63. PubMed ID: 17608467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
    Raval P; Jain M; Goswami A; Basu S; Gite A; Godha A; Pingali H; Raval S; Giri S; Suthar D; Shah M; Patel P
    Bioorg Med Chem Lett; 2011 May; 21(10):3103-9. PubMed ID: 21450468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted α-Isopropoxy Phenylpropanoic Acids with Dual Activators of PPARα and PPARγ.
    Sharma MC
    Interdiscip Sci; 2015 Dec; 7(4):335-45. PubMed ID: 26178333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
    Shen L; Zhang Y; Wang A; Sieber-McMaster E; Chen X; Pelton P; Xu JZ; Yang M; Zhu P; Zhou L; Reuman M; Hu Z; Russell R; Gibbs AC; Ross H; Demarest K; Murray WV; Kuo GH
    Bioorg Med Chem; 2008 Mar; 16(6):3321-41. PubMed ID: 18155554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
    Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
    Bénardeau A; Benz J; Binggeli A; Blum D; Boehringer M; Grether U; Hilpert H; Kuhn B; Märki HP; Meyer M; Püntener K; Raab S; Ruf A; Schlatter D; Mohr P
    Bioorg Med Chem Lett; 2009 May; 19(9):2468-73. PubMed ID: 19349176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.
    Ye XY; Li YX; Farrelly D; Flynn N; Gu L; Locke KT; Lippy J; O'Malley K; Twamley C; Zhang L; Ryono DE; Zahler R; Hariharan N; Cheng PT
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3545-50. PubMed ID: 18511276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation.
    Ye XY; Chen S; Zhang H; Locke KT; O'Malley K; Zhang L; Srivastava R; Miao B; Meyers D; Monshizadegan H; Search D; Grimm D; Zhang R; Lippy J; Twamley C; Muckelbauer JK; Chang C; An Y; Hosagrahara V; Zhang L; Yang TJ; Mukherjee R; Cheng PT; Tino JA
    Bioorg Med Chem Lett; 2010 May; 20(9):2933-7. PubMed ID: 20356736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
    Bhurruth-Alcor Y; Røst T; Jorgensen MR; Kontogiorgis C; Skorve J; Cooper RG; Sheridan JM; Hamilton WD; Heal JR; Berge RK; Miller AD
    Org Biomol Chem; 2011 Feb; 9(4):1169-88. PubMed ID: 21157612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
    Fracchiolla G; Laghezza A; Piemontese L; Tortorella P; Mazza F; Montanari R; Pochetti G; Lavecchia A; Novellino E; Pierno S; Conte Camerino D; Loiodice F
    J Med Chem; 2009 Oct; 52(20):6382-93. PubMed ID: 19775169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.